Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of stable genetic ablation and pharmacological inhibition of SMYD3 on gene expression in CRC cell line (HCT-116)

ABSTRACT: Effect of stable genetic ablation and pharmacological inhibition of SMYD3 on gene expression in CRC cell line (HCT-116)

PROVIDER: PRJNA1101069 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR28709500.fastq.gz	Fastqsanger.gz
	SRR28709501.fastq.gz	Fastqsanger.gz
	SRR28709502.fastq.gz	Fastqsanger.gz
	SRR28709503.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 28

Similar Datasets

Effect of stable genetic ablation and pharmacological inhibition of SMYD3 on gene expression in CRC cell line (HCT-116)

Project description:Cancer stem cells (CSC) are responsible for colorectal cancer (CRC) chemoresistance, recurrence, and metastasis. Therefore, it has become crucial finding critical molecular stemness targets that are essential for tumor growth. Here, we performed an extensive in vitro and in vivo molecular and functional characterization revealing the pivotal role of SMYD3 in CSC biology. Specifically, SMYD3 interacts with and methylates c-MYC at K158 and K163, modulating its transcriptional activity implicated in stemness and colorectal malignancy. Together, all the in vitro data collected, suggest that SMYD3 pharmacological inhibition affects clonogenic and self-renewal potential of patient-derived CRC-SCs and organoids by altering their molecular signature. Moreover, we showed that SMYD3 stable knock-out or its pharmacological inhibition drastically reduced CRC tumorigenicity in vivo, and reduced the metastatic potential of CRC-SCs. Thus, our findings identify SMYD3 as a promising therapeutic target, acting directly on c-MYC, with potential implications for countering CRC-SCs proliferation, chemoresistance, and metastatic dissemination.

2025-06-17 | GSE264157 | GEO

MicroRNA profiling of HCT-116 versus HCT-116 treated with 5-aza-2'-deoxycytidine processing human colon cancer cell lines

Project description:UCRs expression signature of HCT-116 cell lines versus HCT-116 cell line treated with DNA methylation inhibitor 5-aza-2'-deoxycytidine

2010-03-09 | E-MTAB-196 | biostudies-arrayexpress

Effect of pharmacological inhibition of SMYD3 on gene expression in patient-derived CRC-SCs

2025-06-17 | GSE264227 | GEO

Expression data in HCT-116 colon cancer cell treated with SCD1 inhibitor or in SCD1 knocked out HCT-116 cell

Project description:To understand molecular mechanisms underlying the growth inhibitory ativity of Stearoyl-CoA desaturase-1 (SCD1) inhibitor, we performed microarray analysis using HCT-116 colorectal cancer cells, in which SCD1 was pharmacologically blocked or genetically ablated.

2017-08-01 | GSE98364 | GEO

APC ChIP-seq in HCT-116 colon cancer cell line

Project description:Anti-APC ChIP-seq data were collected from HCT-116 cells and 3,985 genomic sequences were found to be enriched in both independent biological replicates.

2018-05-24 | GSE99262 | GEO

RNA-Seq analysis of HCT-116 colon cancer cells upon lysophosphatidic acid treatment

Project description:We report the differential gene expression upon the LPA treatment depicting the invasion/metastasisphenomenon and the lipogenesis effect on the colorectal cancer cells HCT-116

2020-09-19 | GSE104016 | GEO

Gene expression profile of human colorectal carcinoma HCT 116 cell line treated with imipramine

Project description:The study aim is to evaluate to what extent imipramine treatment of HCT-116 colorectal cell lines does affect fascin1-related or cytoskeleton-associated functions

2020-03-23 | GSE125169 | GEO

Identification of HLA class I-presented peptides in MSI CRC model cell line HCT-116

Project description:HCT-116 cells were treated either with 5 µM of the NMD inhibitor 5-azacytidine (PMID: 25319547) or DMSO (negative solvent control) for 24 h to examine differences in HLA class I-mediated peptide presentation. Moreover, data were used for the identification of tumor-specific neoepitopes originating from insertion/deletion mutations due to microsatellite instability.

2021-04-14 | PXD021755 | Pride

Gene alterations by PPAR-gamma agonists in human colorectal adenocarcinoma HCT-116 cells

Project description:We examined the alternation of gene expression by MCC-555, rosiglitazone (RGZ) and 15-deoxy-Δ12, 14-prostaglandin J2 (PGJ2) in human colorectal adenocarcinoma HCT-116 cells. Keywords: effects of PPAR-gamma agonists

2008-06-10 | GSE9183 | GEO

Homo sapiens strain:HCT-116 cell lines

Project description:Homo sapiens strain:HCT-116 cell lines Exome

| PRJNA245458 | ENA